Solid Tumor Clinical Trials

247 recruiting

Solid Tumor Trials at a Glance

1,213 actively recruiting trials for solid tumor are listed on ClinicalTrialsFinder across 6 cities in 63 countries. The largest study group is Phase 1 with 935 trials, with the heaviest enrollment activity in Houston, New York, and Shanghai. Lead sponsors running solid tumor studies include Sichuan Baili Pharmaceutical Co., Ltd., Memorial Sloan Kettering Cancer Center, and Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Treatments under study

About Solid Tumor Clinical Trials

Looking for clinical trials for Solid Tumor? There are currently 247 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,213 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Solid TumorsNeoplasms
National Cancer Institute (NCI)65 enrolled1 locationNCT03366116
Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Metastatic Solid TumorLocally Advanced Solid Tumor
Ipsen114 enrolled12 locationsNCT07213817
Recruiting
Phase 1Phase 2

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Advanced Solid Tumor
Ipsen85 enrolled13 locationsNCT06833008
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Advanced Solid TumorMetastatic Solid Tumor
Ipsen102 enrolled11 locationsNCT07213830
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 2

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Other Solid Tumors, AdultFGFR2 Gene Fusion/Rearrangement
Elevar Therapeutics30 enrolled19 locationsNCT07359820
Recruiting
Phase 1Phase 2

Study in Advanced Solid Tumor Patients

Advanced Solid Tumor
Callio Therapeutics306 enrolled11 locationsNCT07300943
Recruiting
Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled25 locationsNCT05536141
Recruiting
Early Phase 1

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

Advanced Solid Tumors
Base Therapeutics (Shanghai) Co., Ltd.18 enrolled1 locationNCT07561437
Recruiting
Phase 1Phase 2

Study of ZGGS34 in Participants With Advanced Solid Tumors

Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd400 enrolled1 locationNCT07258121
Recruiting
Phase 1Phase 2

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Gastric CancerSolid Tumors
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 1Phase 2

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd181 enrolled12 locationsNCT05898399
Recruiting
Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Solid TumorLymphomaGIST+5 more
ITM Solucin GmbH20 enrolled5 locationsNCT06441331
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Phase 1

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Solid Tumor
Sichuan University24 enrolled1 locationNCT06349837
Recruiting
Phase 1Phase 2

HEC169096 in Participants With Advanced Solid Tumors

Advanced Solid Tumor
Sunshine Lake Pharma Co., Ltd.456 enrolled1 locationNCT05451602
Recruiting
Phase 1

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

Solid Tumors (Phase 1)
Haisco Pharmaceutical Group Co., Ltd.159 enrolled2 locationsNCT07561554